ASPL Fusion careers

ASPL Fusion (Agnira Sanlayan Pvt. Ltd.) is building India's first commercial neutron technology platform. Starting with BNCT cancer therapy and medical isotope production, our technology trajectory leads to clean fusion energy.

Our platform addresses three massive markets:

1. Cancer Therapy (BNCT): Building India's first Boron Neutron Capture Therapy centre — a targeted radiation treatment that kills tumour cells while sparing healthy tissue. 30+ million cancer patients could benefit globally.

2. Medical Isotopes: India imports 100% of its diagnostic and therapeutic isotopes. We are building domestic production capability for Tc-99m, Lu-177, Cu-64, and 7 other critical isotopes using our Gas-Dynamic Trap fusion device.

3. Clean Energy: Our fusion technology trajectory, built on revenue-generating medical applications, leads to commercial fusion power by 2038-2040.

Founded by Prof. Prabhat Ranjan (former Director, Institute for Plasma Research — India's national fusion lab) and a team of nuclear scientists and engineers.

Key facts:
- DPIIT startup recognition: DIPP222699
- Pragmatic four-phase development strategy generating revenue from Rung 0
- World-class advisory board including Prof. Y.C. Saxena (former Head, FCIPT/IPR)
- Deep partnerships with IPR, BARC, and IREL for technology and regulatory access
- Accelerator-based neutron source (2.5 MeV proton beam on Li-7 target)
- Proprietary simulation IP validated against IPR experimental neutron data

We are not waiting for fusion to work before generating revenue. Our near-term medical applications (BNCT, isotopes) fund the long-term fusion mission. This is the pragmatic path to fusion energy.